The Plasmid DNA Manufacturing Market, estimated at USD 1,353.0 Mn in 2025, is expected to exhibit a CAGR of 22.5% and reach USD 5,600.8 Mn by 2032.
The market growth is fueled by rising demand for advanced biotechnology solutions that improve healthcare outcomes, along with increasing adoption in areas such as drug development, diagnostics, and personalized medicine. Innovations in genomics, cell and gene therapies, and biomanufacturing, supported by strong R&D investments, are enhancing treatment effectiveness, efficiency, and accessibility. Furthermore, favorable regulatory support, strategic collaborations, and the growing focus on precision medicine are accelerating market expansion and opening new opportunities for industry participants.
The key players in the market are focusing on adoption of inorganic growth strategies such as partnerships, and collaborations, in order to strengthen their market presence in the global plasmid DNA manufacturing market is expected to drive the market growth over the forecast period. For instance, in February 2025, Novartis AG, a global healthcare company, collaborated with Bill & Melinda Gates Foundation, a non-profit foundation fighting disease, inequity, and poverty across the globe. This strategic alliance aims to bring together gene therapy and drug discovery proficiency of Novartis with charitable objectives of Gates Foundation to discover and develop an approachable in vivo gene therapy to treat Sickle cell disease.
Global Plasmid DNA Manufacturing Market– Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that first appeared in Wuhan (province of Hubei, China) in the last months of 2025 as "coronavirus disease 2025," or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and health of every country in the world.
The COVID-19 can affect the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries such as India, China, Brazil, and others are facing problems with regards to the transportation of drugs from one place to another.
The key players operating in the market are focusing on development of DNA vaccines for the treatment of Covid -19. For instance, In April 2025, INOVIO pharmaceuticals Inc. entered into an agreement to expand its manufacturing partnership with the German contract manufacturer Richter-Helm BioLogics GmbH & Co. KG, to support large-scale manufacturing of INOVIO's investigational DNA vaccine INO-4800, which currently is in Phase 1 clinical testing in the U.S. for COVID-19 and could potentially advance to Phase 2/3 efficacy trials this summer.
Global Plasmid DNA Manufacturing Market: Key Developments
In June 2025, Charles River Laboratories International, Inc., American pharmaceutical company, announced that it had completed acquisition of Vigene Biosciences, Inc., a premier, gene therapy contract development and manufacturing organization (CDMO), providing viral vector-based gene delivery solutions. Vigene Biosciences offers high-quality, research grade and CGMP plasmid DNA. The acquisition complements Charles River’s existing cell and gene therapy contract manufacturing capabilities and establishes an end-to-end, gene-modified cell therapy solution in the U.S.
In March 2025, Texas-based GMP Plasmid CDMO VGXI, Inc. and Geneos Therapeutics, Inc. expanded their Clinical Manufacturing Supply Agreement in support of Geneos’ ongoing GT-30 Phase Ib/IIa Clinical Trial for advanced hepatocellular carcinoma (HCC).